Tectonic Therapeutic (TECX) Liabilities and Shareholders Equity (2017 - 2026)

Tectonic Therapeutic (TECX) has reported Liabilities and Shareholders Equity for 10 consecutive years, with $246.6 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity fell 21.68% year-over-year to $246.6 million; the TTM figure through Mar 2026 stood at $1.1 billion (up 30.06% YoY), while the FY2025 annual figure was $261.0 million, up 70.72% from the prior year.
• Liabilities and Shareholders Equity eased to $246.6 million in Q1 2026 per TECX's latest filing, from $261.0 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $314.8 million in Q1 2025 and bottomed at $39.4 million in Q4 2023.
• Historically, Liabilities and Shareholders Equity has averaged $172.0 million across 5 years, with a median of $152.9 million in 2024.
• Annual changes were most pronounced in 2023 — Liabilities and Shareholders Equity sank 62.1% — and 2024, when it soared 288.09%.
• Tectonic Therapeutic's Liabilities and Shareholders Equity stood at $103.9 million in 2022, then tumbled by 62.1% to $39.4 million in 2023, then jumped by 288.09% to $152.9 million in 2024, then jumped by 70.72% to $261.0 million in 2025, then fell by 5.54% to $246.6 million in 2026.
• Business Quant data shows TECX's Liabilities and Shareholders Equity at $246.6 million in Q1 2026, $261.0 million in Q4 2025, and $277.0 million in Q3 2025.